Sebastian Szymanek

• Continuation of sales and marketing performance growth as well as development of the organization's digital environment • Strengthening of the organization’s marketplace in the Consumer Healthcare segment • Preparing the organization to new legal and commercial challenges • Influencing the Polpharma Group strategy • Active participation in the dialogue with Polish pharmaceutical market decision-makers • Polpharma continues to lead market growth, high above the market dynamics average • 2014-2017 – fast-growing market share in the CHC segment – taking the lead at the end of 2017 with 7.7% of MktShV • Shift from multichannel to omnichannel client communication • Data systems allowing to take business decisions in real time • Implementing innovative digital solutions o Regular search for new synergic digital solutions in the market o Creating business ecosystem based on cooperation with partners (digital suppliers, start-ups) • As the Vice-President of the Board influencing Polpharma Group strategies covering decisions regarding countries, products, commercial models, roll-outs • Building the organization’s CSR image (no. 1 in the 2018 Gazeta Prawna ranking) and the corporate image as the National Champion (no. 5 in the market according to the Polityka Insight report)

• Building the largest sales and marketing team in Poland comprising 1000+ people • Preparing and implementing sales and marketing, and portfolio strategy as well as client channels • Developing Polpharma’s presence in new therapeutic areas, such as: ophthalmology, gynecology, dermatology, and allergology • Implementing new HR policies, and new talent management areas, such as: efficiency, satisfaction, motivation, and loyalty • Acquiring Polfa Warszawa and joining its portfolio and sales force with the Polpharma Group resulting in doubling sales numbers of products from the Polfa Warszawa portfolio within 4 years • Carrying out the “7x NAJ” (“7x the BEST”) Program for Polpharma, standing for: o The BEST organization size-wise o The BEST in terms of growth from among top 10 generic companies in Poland o The BEST company according to our clients o The BEST employer o The BEST efficiency of the salesforce promotional activities o The BEST sales performance o The BEST company in terms of marketing and sales efficiency RESULTS o In 2011 Polpharma took the lead of the Polish pharmaceutical market with 5.4% of MktShV o Since 2010 trend shift and dynamic growth above the market average (+6.5% vs. PY); in 2011 Polpharma’s performance was above the top 10 generic companies (PPG 8.9%); in 2012 – the year of introducing new reimbursement law – most companies recorded decreased performance, whereas Polpharma’s PPG was +1.8%; in 2013 - +7.5%; in 2014 - +6.5%, i.e. Polpharma’s growth was above the market average (CMI_IMS data) o The highest levels of satisfaction expressed by doctors and pharmacists. From 2010 to 2014 doctors’ satisfaction level grew from 14.5% to 21%, pharmacists’ satisfaction level grew from 20% to 36% (Cegedime survey) o Salesforce turnover from 17% to 7% o Highest levels of employee satisfaction, motivation, and loyalty among top pharmaceutical companies (3 editions of the Sequence study)

• Initiating and developing a new 38-person sales and marketing team responsible for psychiatric drugs • Expanding the product portfolio and gaining market share • Currently the department comes second in the Polish psychiatric drug segment • Overtaking the 34-people Hospital team • Implementing new working standards and sales system in the team • Initiating and developing the marketing function – developing drug portfolio and market share growth • Currently every fourth drug packaging sold to hospitals is a Polpharma drug

Psychiatry, Alergology, Urology, Internal Medicine



